Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects

Kyoung Ah Kim, Ji-Young Park

Research output: Contribution to journalArticle

Abstract

Objective: Febuxostat is a selective inhibitor of xanthine oxidase, which is used to manage hyperuricemia in patients with gout. The objective of the study was to compare the pharmacokinetics of two different strength of febuxostat formulations (80 mg and 40 mg). Methods: A randomized, single-dose, open-label, two-period, two-sequence crossover study with a 7-day washout period was conducted in 30 healthy male subjects. Participants received either reference (1 × 80 mg) or test (2 × 40 mg) formulations during the first period and the alternative formulation during the second period. Plasma samples for the drug analysis were collected up to 24 hours after treatment. Results: All pharmacokinetic parameters were comparable between the two formulations. The observed mean Cmax, AUClast, and AUC values for the reference formulation were 3,670 ng/mL, 12,086 ng×h/mL, and 12,880 ng×h/mL, respectively. Corresponding values for the test formulation were 4,108 ng/mL, 12,689 ng×h/mL, and 13,278 ng×h/mL, respectively. The geometric mean ratios (90% CI) between the two formulations were 1.1273 (1.0286 - 1.2355) for Cmax, 1.054 (1.0115 - 1.0980) for AUClast, and 1.0395 (0.9959 - 1.0851) for AUC. The changes of serum uric acid at 24 hours after reference and test formations were comparable (-1.36 mg/dL for reference and -1.37 mg/dL for test; p = 0.892). Conclusion: The results of the present study indicated that the reference and test formulations have comparable pharmacokinetics and that these two formulations meet the regulatory criteria for bioequivalence. In addition, the reduction of serum UA levels in the reference formulation was similar to that of the test formulation after a single dose.

Original languageEnglish
Pages (from-to)667-673
Number of pages7
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume53
Issue number8
DOIs
Publication statusPublished - 2015 Aug 1
Externally publishedYes

Fingerprint

Uric Acid
Healthy Volunteers
Pharmacokinetics
Area Under Curve
Hyperuricemia
Therapeutic Equivalency
Xanthine Oxidase
Gout
Serum
Cross-Over Studies
Reference Values
Pharmaceutical Preparations
Febuxostat
Therapeutics

Keywords

  • Bioequivalence
  • Febuxostat
  • Pharmacokinetic equivalence
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{d2c650d0c8d74094afae81615e321fe1,
title = "Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects",
abstract = "Objective: Febuxostat is a selective inhibitor of xanthine oxidase, which is used to manage hyperuricemia in patients with gout. The objective of the study was to compare the pharmacokinetics of two different strength of febuxostat formulations (80 mg and 40 mg). Methods: A randomized, single-dose, open-label, two-period, two-sequence crossover study with a 7-day washout period was conducted in 30 healthy male subjects. Participants received either reference (1 × 80 mg) or test (2 × 40 mg) formulations during the first period and the alternative formulation during the second period. Plasma samples for the drug analysis were collected up to 24 hours after treatment. Results: All pharmacokinetic parameters were comparable between the two formulations. The observed mean Cmax, AUClast, and AUC∞ values for the reference formulation were 3,670 ng/mL, 12,086 ng×h/mL, and 12,880 ng×h/mL, respectively. Corresponding values for the test formulation were 4,108 ng/mL, 12,689 ng×h/mL, and 13,278 ng×h/mL, respectively. The geometric mean ratios (90{\%} CI) between the two formulations were 1.1273 (1.0286 - 1.2355) for Cmax, 1.054 (1.0115 - 1.0980) for AUClast, and 1.0395 (0.9959 - 1.0851) for AUC∞. The changes of serum uric acid at 24 hours after reference and test formations were comparable (-1.36 mg/dL for reference and -1.37 mg/dL for test; p = 0.892). Conclusion: The results of the present study indicated that the reference and test formulations have comparable pharmacokinetics and that these two formulations meet the regulatory criteria for bioequivalence. In addition, the reduction of serum UA levels in the reference formulation was similar to that of the test formulation after a single dose.",
keywords = "Bioequivalence, Febuxostat, Pharmacokinetic equivalence, Pharmacokinetics",
author = "Kim, {Kyoung Ah} and Ji-Young Park",
year = "2015",
month = "8",
day = "1",
doi = "10.5414/CP202032",
language = "English",
volume = "53",
pages = "667--673",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "8",

}

TY - JOUR

T1 - Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects

AU - Kim, Kyoung Ah

AU - Park, Ji-Young

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective: Febuxostat is a selective inhibitor of xanthine oxidase, which is used to manage hyperuricemia in patients with gout. The objective of the study was to compare the pharmacokinetics of two different strength of febuxostat formulations (80 mg and 40 mg). Methods: A randomized, single-dose, open-label, two-period, two-sequence crossover study with a 7-day washout period was conducted in 30 healthy male subjects. Participants received either reference (1 × 80 mg) or test (2 × 40 mg) formulations during the first period and the alternative formulation during the second period. Plasma samples for the drug analysis were collected up to 24 hours after treatment. Results: All pharmacokinetic parameters were comparable between the two formulations. The observed mean Cmax, AUClast, and AUC∞ values for the reference formulation were 3,670 ng/mL, 12,086 ng×h/mL, and 12,880 ng×h/mL, respectively. Corresponding values for the test formulation were 4,108 ng/mL, 12,689 ng×h/mL, and 13,278 ng×h/mL, respectively. The geometric mean ratios (90% CI) between the two formulations were 1.1273 (1.0286 - 1.2355) for Cmax, 1.054 (1.0115 - 1.0980) for AUClast, and 1.0395 (0.9959 - 1.0851) for AUC∞. The changes of serum uric acid at 24 hours after reference and test formations were comparable (-1.36 mg/dL for reference and -1.37 mg/dL for test; p = 0.892). Conclusion: The results of the present study indicated that the reference and test formulations have comparable pharmacokinetics and that these two formulations meet the regulatory criteria for bioequivalence. In addition, the reduction of serum UA levels in the reference formulation was similar to that of the test formulation after a single dose.

AB - Objective: Febuxostat is a selective inhibitor of xanthine oxidase, which is used to manage hyperuricemia in patients with gout. The objective of the study was to compare the pharmacokinetics of two different strength of febuxostat formulations (80 mg and 40 mg). Methods: A randomized, single-dose, open-label, two-period, two-sequence crossover study with a 7-day washout period was conducted in 30 healthy male subjects. Participants received either reference (1 × 80 mg) or test (2 × 40 mg) formulations during the first period and the alternative formulation during the second period. Plasma samples for the drug analysis were collected up to 24 hours after treatment. Results: All pharmacokinetic parameters were comparable between the two formulations. The observed mean Cmax, AUClast, and AUC∞ values for the reference formulation were 3,670 ng/mL, 12,086 ng×h/mL, and 12,880 ng×h/mL, respectively. Corresponding values for the test formulation were 4,108 ng/mL, 12,689 ng×h/mL, and 13,278 ng×h/mL, respectively. The geometric mean ratios (90% CI) between the two formulations were 1.1273 (1.0286 - 1.2355) for Cmax, 1.054 (1.0115 - 1.0980) for AUClast, and 1.0395 (0.9959 - 1.0851) for AUC∞. The changes of serum uric acid at 24 hours after reference and test formations were comparable (-1.36 mg/dL for reference and -1.37 mg/dL for test; p = 0.892). Conclusion: The results of the present study indicated that the reference and test formulations have comparable pharmacokinetics and that these two formulations meet the regulatory criteria for bioequivalence. In addition, the reduction of serum UA levels in the reference formulation was similar to that of the test formulation after a single dose.

KW - Bioequivalence

KW - Febuxostat

KW - Pharmacokinetic equivalence

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84941101423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941101423&partnerID=8YFLogxK

U2 - 10.5414/CP202032

DO - 10.5414/CP202032

M3 - Article

VL - 53

SP - 667

EP - 673

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 8

ER -